Search filters

List of works by Sophie Postel-Vinay

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

scientific article

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

scientific article published on 12 August 2013

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

scientific article published on 18 August 2017

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

scientific article published on 02 December 2009

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

scientific article

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

scientific article

Chromatin Regulators as a Guide for Cancer Treatment Choice

scientific article published on 16 May 2016

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

scientific article published on May 2009

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

scientific article

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise

scientific article published on 30 September 2019

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma

scientific article (publication date: 12 February 2012)

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

scientific article published on 15 February 2018

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

scientific article

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

scientific article published on 15 June 2017

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?

scientific article published on 06 November 2019

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

scientific article

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

scientific article

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

scientific article published on 7 November 2017

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

scientific article published on 2 March 2016

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

scientific article

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

scientific article published on 16 January 2013

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

scientific article

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

scientific article published on 09 June 2017

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

article by Roman M Chabanon et al published 1 March 2019 in Journal of Clinical Investigation

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

scientific article published on 15 September 2015

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

scientific article published on 4 November 2016

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

scientific article

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

scientific article published on 20 February 2017

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

scientific article

Rationale for anti-OX40 cancer immunotherapy

scientific article

Reovirus: Rationale and clinical trial update

scientific article

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

scientific article

Targeting FGFR Signaling in Cancer

scientific article published on June 2015

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

scientific article

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

scientific article published on 14 February 2012

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

scientific article

Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?

scientific article

Paulina is supported by:

About Paulina

Help